ATE366813T1 - Neue peptide - Google Patents

Neue peptide

Info

Publication number
ATE366813T1
ATE366813T1 AT00946453T AT00946453T ATE366813T1 AT E366813 T1 ATE366813 T1 AT E366813T1 AT 00946453 T AT00946453 T AT 00946453T AT 00946453 T AT00946453 T AT 00946453T AT E366813 T1 ATE366813 T1 AT E366813T1
Authority
AT
Austria
Prior art keywords
amino acid
new peptides
compound
activity
replaced
Prior art date
Application number
AT00946453T
Other languages
English (en)
Inventor
Kenji Kangawa
Masayasu Kojima
Hiroshi Hosoda
Hisayuki Matsuo
Yoshiharu Minamitake
Original Assignee
Kenji Kangawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenji Kangawa filed Critical Kenji Kangawa
Application granted granted Critical
Publication of ATE366813T1 publication Critical patent/ATE366813T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AT00946453T 1999-07-23 2000-07-24 Neue peptide ATE366813T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21000299 1999-07-23
JP33884199 1999-11-29
JP2000126623 2000-04-26

Publications (1)

Publication Number Publication Date
ATE366813T1 true ATE366813T1 (de) 2007-08-15

Family

ID=27329078

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07006224T ATE449174T1 (de) 1999-07-23 2000-07-24 Neue peptide
AT00946453T ATE366813T1 (de) 1999-07-23 2000-07-24 Neue peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07006224T ATE449174T1 (de) 1999-07-23 2000-07-24 Neue peptide

Country Status (16)

Country Link
US (5) US7385026B1 (de)
EP (3) EP1197496B8 (de)
JP (2) JP3471780B2 (de)
KR (1) KR100827973B1 (de)
CN (2) CN100506844C (de)
AT (2) ATE449174T1 (de)
AU (2) AU784035B2 (de)
BR (2) BR0012688A (de)
CA (2) CA2380058C (de)
CY (2) CY1107724T1 (de)
DE (2) DE60043361D1 (de)
DK (2) DK1795598T3 (de)
ES (3) ES2335235T3 (de)
IL (2) IL147652A0 (de)
PT (2) PT1197496E (de)
WO (1) WO2001007475A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449174T1 (de) * 1999-07-23 2009-12-15 Kenji Kangawa Neue peptide
EP1232175B1 (de) 1999-11-22 2009-07-08 ZymoGenetics, Inc. Methode zur bildung einen peptid-rezeptor komplex mit zsig33 polypeptiden.
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
WO2001085804A1 (fr) 2000-05-12 2001-11-15 Kaneka Corporation Procede de purification de polymere vinylique
CA2411667A1 (en) 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
CA2416643A1 (en) * 2000-07-24 2002-01-31 Ardana Bioscience Limited Ghrelin antagonists
WO2003084983A1 (fr) * 2002-04-11 2003-10-16 Daiichi Suntory Pharma Co., Ltd. Procede de production d'un peptide modifie
WO2003097083A1 (fr) * 2002-05-21 2003-11-27 Daiichi Suntory Pharma Co.,Ltd. Compositions medicinales contenant de la ghreline
MXPA04011247A (es) * 2002-07-19 2005-02-17 Cytos Biotechnology Ag Conjugados portadores de grelina.
EP2258381A3 (de) 2002-07-23 2011-11-02 Ipsen Pharma Ghrelin analoge
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
CA2496687A1 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
EP1407779A1 (de) * 2002-10-10 2004-04-14 Gastrotech A/S Verwendung von Ghrelin zur Behandlung von vermindertem Körpergewicht und Körperfett in Individuen mit Gastrektomie
ES2383685T3 (es) 2003-04-30 2012-06-25 Kenji Kangawa Preventivos o remedios para hepatopatía
EP1633397A2 (de) * 2003-06-04 2006-03-15 Eli Lilly And Company Anti-ghrelin fab antikörper
WO2005026211A2 (en) * 2003-09-05 2005-03-24 Eli Lilly And Company Anti-ghrelin antibodies
CN1321131C (zh) * 2003-12-26 2007-06-13 李宁 猪Ghrelin衍生物及其编码基因与应用
US20050191317A1 (en) * 2004-01-20 2005-09-01 Cytos Biotechnology Ag Ghrelin-carrier conjugates
US7026175B2 (en) 2004-03-29 2006-04-11 Applied Materials, Inc. High throughput measurement of via defects in interconnects
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
JP2007532495A (ja) * 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
CA2566703A1 (en) * 2004-05-11 2005-11-24 Vishwa Deep Dixit Methods of inhibiting proinflammatory cytokine expression using ghrelin
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
JP2008515771A (ja) * 2004-07-14 2008-05-15 イーライ リリー アンド カンパニー 抗グレリン抗体
EP1812045A2 (de) * 2004-10-27 2007-08-01 Gastrotech Pharma A/S Verwendung von sekretagoga bei der behandlung von patienten nach einer organtransplantation
WO2006045319A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
EP1828243A2 (de) * 2004-11-30 2007-09-05 Gastrotech Pharma A/S Liganden des die wachstumshormonsekretion anregenden rezeptors 1a
EP1862173B1 (de) * 2005-02-23 2014-12-17 Kyoto University Promotor der regeneration einer pankreatischen zelle und promotor der insulinproduktion in einer pankreatischen zelle
EP1856154A1 (de) * 2005-02-23 2007-11-21 Eli Lilly And Company Humanisierte antighrelin-antikörper
RU2420305C2 (ru) 2005-09-29 2011-06-10 Ипсен Фарма С.А.С. Композиции и способы стимуляции двигательной функции желудочно-кишечного тракта
BRPI0618841A2 (pt) 2005-11-21 2011-09-13 Univ Miyazaki agente terapêutico acelerador de recuperação dérmica contendo desacil grelina e derivados desta como ingrediente ativo
RU2420306C2 (ru) * 2005-11-21 2011-06-10 Юниверсити Оф Миязаки ТЕРАПЕВТИЧЕСКОЕ СРЕДСТВО ДЛЯ УСКОРЕННОГО ЗАЖИВЛЕНИЯ КОЖИ, СОДЕРЖАЩЕЕ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ГРЕЛИН И ЕГО ПРОИЗВОДНЫЕ ИЛИ ВЕЩЕСТВО, ВОЗДЕЙСТВУЮЩЕЕ НА РЕЦЕПТОР GHS-R1a
EP2012809B1 (de) 2006-03-10 2013-05-22 Ipsen Pharma Verwendung eines ghrelin-agonisten zur erhöhung der katabolischen wirkung einer glukokortikoidbehandlung
RU2470940C2 (ru) 2006-03-13 2012-12-27 Лиат МИНТЦ Применение варианта сплайсинга грелина для лечения кахексии, и/или анорексии, и/или анорексии-кахексии, и/или нарушения питания, и/или липодистрофии, и/или мышечного истощения, и/или стимуляции аппетита
WO2008016976A2 (en) * 2006-08-01 2008-02-07 The Scripps Research Institute Vaccines and methods for controlling adiposity
US20100143310A1 (en) 2006-08-11 2010-06-10 Japan As Represented By President Of National Cardiovascular Center SPINAL NERVE REPAIR PROMOTING THERAPEUTICS CONTAINING GHRELIN OR ITS DERIVATIVES OR SUBSTANCES THAT ACT ON GHS-R1a AS AN ACTIVE INGREDIENT
RU2009108640A (ru) * 2006-08-11 2010-09-20 Юниверсити Оф Миязаки (Jp) Лекарственные средства, усиливающие репарацию спинно-мозговых нервов, содержащие в качестве активного ингредиента дезацилгрелин или его производные
EP2083842B1 (de) * 2006-09-27 2013-08-28 Ipsen Pharma S.A.S. Analoga von ghrelin mit substitution am n-terminus
CA2698582C (en) 2008-05-23 2016-09-13 Asubio Pharma Co., Ltd. Peptide having an extending action for half-life of object peptide in plasma
LT2393828T (lt) 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
CA2761901C (en) * 2009-05-12 2019-08-13 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
EP2524697B1 (de) 2010-01-15 2016-09-21 University of Miyazaki Ghrelin zur förderung der erholung von tieren in medizinischer behandlung
US9315546B2 (en) 2010-06-16 2016-04-19 The Administrators Of The Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
JP5999712B2 (ja) 2011-03-03 2016-09-28 国立大学法人 宮崎大学 高体温治療剤
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
KR102057356B1 (ko) 2012-02-27 2019-12-18 아뮤닉스 파마슈티컬스, 인크. Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
CN104302177B (zh) 2012-05-17 2019-05-28 延伸生物科学股份有限公司 用于改进的药物递送的载体
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
BR112015009107A2 (pt) 2012-10-24 2017-11-14 Daiichi Sankyo Co Ltd agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo
JP6143270B2 (ja) * 2013-01-31 2017-06-07 学校法人東京薬科大学 マイオスタチン阻害ペプチド
EP2979702A4 (de) * 2013-03-25 2016-11-16 Zeria Pharm Co Ltd Gastrokinetische postprandiale mittel
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
CN109879935B (zh) * 2019-03-04 2020-11-20 南京工业大学 一种多肽的液相合成方法
KR20220131221A (ko) 2019-11-13 2022-09-27 아뮤닉스 파마슈티컬스, 인크. 바코드화된 xten 폴리펩티드 및 이의 조성물, 및 이의 제조 방법 및 사용 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
ES2185628T3 (es) * 1992-04-07 2003-05-01 Scripps Research Inst Procedimiento para preparar proteinas modificadas.
IL118473A0 (en) 1995-06-02 1996-09-12 Suntory Ltd Staphylococcus aureus V8 protease genes coding therefor and a method for the production thereof
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
JP3982866B2 (ja) 1996-03-04 2007-09-26 アスビオファーマ株式会社 分泌型Ｋｅｘ２誘導体の製造方法
WO1999063088A2 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
CN1170933C (zh) * 1997-03-24 2004-10-13 津莫吉尼蒂克斯公司 促胃动素同系物
US6420521B1 (en) * 1999-06-30 2002-07-16 Zymogenetics, Inc. Short gastrointestinal peptides
ATE449174T1 (de) * 1999-07-23 2009-12-15 Kenji Kangawa Neue peptide

Also Published As

Publication number Publication date
EP2119785A1 (de) 2009-11-18
CA2696819A1 (en) 2001-02-01
PT1795598E (pt) 2010-01-05
DE60035502T2 (de) 2008-03-20
DK1795598T3 (da) 2010-02-01
CY1109714T1 (el) 2014-08-13
EP1795598A1 (de) 2007-06-13
KR100827973B1 (ko) 2008-05-21
US8524871B2 (en) 2013-09-03
AU6023100A (en) 2001-02-13
CN100506844C (zh) 2009-07-01
ES2288151T3 (es) 2008-01-01
EP2119785B1 (de) 2013-03-13
PT1197496E (pt) 2007-08-29
US9573986B2 (en) 2017-02-21
BRPI0012688B8 (pt) 2021-05-25
JP2004000251A (ja) 2004-01-08
CA2380058C (en) 2011-08-09
EP1197496A1 (de) 2002-04-17
US20130172251A1 (en) 2013-07-04
AU2006201580B2 (en) 2009-01-08
CN1362968A (zh) 2002-08-07
US8227570B2 (en) 2012-07-24
IL147652A0 (en) 2002-08-14
EP1197496A4 (de) 2002-11-20
DK1197496T3 (da) 2007-10-22
BR0012688A (pt) 2002-04-16
US20100240866A1 (en) 2010-09-23
CA2380058A1 (en) 2001-02-01
US20090170763A1 (en) 2009-07-02
WO2001007475A1 (fr) 2001-02-01
JP3471780B2 (ja) 2003-12-02
US9938332B2 (en) 2018-04-10
US7385026B1 (en) 2008-06-10
EP1197496B8 (de) 2007-10-03
DE60035502D1 (de) 2007-08-23
US20110184153A1 (en) 2011-07-28
JP4227857B2 (ja) 2009-02-18
IL147652A (en) 2010-04-29
AU2006201580A1 (en) 2006-05-18
CY1107724T1 (el) 2013-04-18
CN101693736A (zh) 2010-04-14
KR20020026543A (ko) 2002-04-10
CN101693736B (zh) 2020-09-11
CA2696819C (en) 2015-07-07
EP1795598B1 (de) 2009-11-18
DE60043361D1 (de) 2009-12-31
EP1197496B1 (de) 2007-07-11
BRPI0012688B1 (pt) 2018-06-05
AU784035B2 (en) 2006-01-19
ATE449174T1 (de) 2009-12-15
ES2335235T3 (es) 2010-03-23
ES2401939T3 (es) 2013-04-25

Similar Documents

Publication Publication Date Title
ATE366813T1 (de) Neue peptide
MXPA04005906A (es) Cis-2,4,5-trifenil-.imidazolinas y uso de la misma para tratamiento de tumores.
ATE497390T1 (de) Neue therapeutische verwendung von smr-1 peptide
DE69220861D1 (de) Zyklische Peptide und ihre Verwendung
HK1040738A1 (en) Human parathyroid hormone modifications, preparation and use
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
EP0270214A3 (de) Vasopressinantagonisten
BR0214363A (pt) Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção
DE602004023827D1 (de) Ionenkanalaktivität hemmende niedrigmolekulare peptide
BR9712033A (pt) Composição farmacêutica para tratamento de doenças virais.
DE50307025D1 (de) Zubereitungen zur intranasalen applikation ausgewählter, von aminosäuren abgeleiteter cgrp-antagonisten
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
GB0207644D0 (en) Peptides and their use
EP1467207A4 (de) Screening-verfahren
EP1760087A4 (de) Neuer proteinkomplex und anwendungen davon
WO2003022300A1 (fr) Remedes prophylactiques et curatifs contre les maladies des os et des articulations
WO2003029290A1 (fr) Transporteur de medicament et son utilisation
TH26711A (th) " สิ่งที่คล้ายกันของปัจจัยหลั่งฮอโมนของการเจริญเติบโต "
EP1308512A4 (de) Neuartige proteine und deren dna
ATE178071T1 (de) Endothelin-antagonisierendes peptid
WO1999060117A3 (fr) Polypeptide prax-1